(Total Views: 711)
Posted On: 11/03/2017 10:39:45 AM
Post# of 83
Great time to load up nowafter they resubmit the NDA for Rizaport early this week .GL
RedHill Biopharma and IntelGenx Submit New Drug Application to FDA for RIZAPORT® for Migraines..November 1, 2017
https://finance.yahoo.com/news/redhill-biopha...00087.html
Market Cap : US$48 Million / Cash US$8.2 million /very low burn-rate of ~$700K a Quarter =Cash untill 2020+ EXCLUDING payments from new partnerships ,profitability expected quickly with approval for Rizaport and Tadalafil both approval expected in 2018, if everything goes well then this stock could run to $10 even then it wouldnt be expensive .
Intelgenx (IGXT)
Markt-Cap $48 Million
Cash 8.1 Million
Price: $0.73
FDA Decision for Rizaport(Migraine) in Q2/2018 (Peak Sales $60-80 Million)
NDA submission for Tadalafil (erectile dysfunction) this Quarter >> FDA approval in 2H 2018 (Peak Sales $150++ Million)
Start Phase 2a for Montulukast (Alzheimer disease) this Quarter >> Phase 2a Results in 1H/2018 (Potential BLOCKBUSTER Drug)
Opioid dependence drug partnered with Par Pharma >> FDA approval depends on patent ruling (Peak Sales $100++ Million) 30-Month Stay already expired
MEGA Pipeline
http://s2.q4cdn.com/790425727/files/images/20...y-2017.jpg
Presentation
http://s2.q4cdn.com/790425727/files/doc_prese..._final.pdf
https://investorintel.com/sectors/biotech/bio...lm-market/
RedHill Biopharma and IntelGenx Submit New Drug Application to FDA for RIZAPORT® for Migraines..November 1, 2017
https://finance.yahoo.com/news/redhill-biopha...00087.html
Market Cap : US$48 Million / Cash US$8.2 million /very low burn-rate of ~$700K a Quarter =Cash untill 2020+ EXCLUDING payments from new partnerships ,profitability expected quickly with approval for Rizaport and Tadalafil both approval expected in 2018, if everything goes well then this stock could run to $10 even then it wouldnt be expensive .
Intelgenx (IGXT)
Markt-Cap $48 Million
Cash 8.1 Million
Price: $0.73
FDA Decision for Rizaport(Migraine) in Q2/2018 (Peak Sales $60-80 Million)
NDA submission for Tadalafil (erectile dysfunction) this Quarter >> FDA approval in 2H 2018 (Peak Sales $150++ Million)
Start Phase 2a for Montulukast (Alzheimer disease) this Quarter >> Phase 2a Results in 1H/2018 (Potential BLOCKBUSTER Drug)
Opioid dependence drug partnered with Par Pharma >> FDA approval depends on patent ruling (Peak Sales $100++ Million) 30-Month Stay already expired
MEGA Pipeline
http://s2.q4cdn.com/790425727/files/images/20...y-2017.jpg
Presentation
http://s2.q4cdn.com/790425727/files/doc_prese..._final.pdf
https://investorintel.com/sectors/biotech/bio...lm-market/
(0)
(0)
